These findings may also inform the mechanism-based treatment of PHIP variant carriers with a melanocortin receptor agonist currently in clinical trials, which leads to significant weight loss in severe obesity due to complete POMC deficiency (Kühnen et al., 2016). Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.